NCT01677897View on ClinicalTrials.gov

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Metformin

Adding Metformin to Abiraterone in case of PSA-Progression

Trial Locations (1)

7000

Kantonsspital Graubünden, Chur

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Kantonsspital Graubünden

OTHER

NCT01677897 - Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients | Biotech Hunter | Biotech Hunter